caa a22 4500 445889349 CHVBK 20180317145611.0 cr unu---uuuuu 170323e20111101xx s 000 0 eng 10.1007/s00535-011-0444-4 doi (NATIONALLICENCE)springer-10.1007/s00535-011-0444-4 Reduction of liver stiffness by antiviral therapy in chronic hepatitis B [Elektronische Daten] [Keisuke Osakabe, Naohiro Ichino, Toru Nishikawa, Hiroko Sugiyama, Miho Kato, Shiho Kitahara, Senju Hashimoto, Naoto Kawabe, Masao Harata, Yoshifumi Nitta, Michihito Murao, Takuji Nakano, Hiroaki Shimazaki, Yuko Arima, Koji Suzuki, Kentaro Yoshioka] Background: Liver stiffness (LS) has been reported to correlate with fibrosis stage (F). The correlation between LS and fibrosis stage and the reduction of LS by antiviral therapy were examined in patients with hepatitis B infection. Methods: LS was measured by FibroScan in 212 patients infected with hepatitis B virus. Liver biopsies were done in 51 patients. Changes of LS were assessed in 29 patients treated with nucleotide or nucleoside analogs and 52 patients without antiviral therapy. Results: LS was significantly correlated with fibrosis stage (ρ=0.686, P<0.0001). The optimal cut-off values of LS were 7.1kPa for F≥2, 10.7kPa for F≥3, and 16.0kPa for F4. LS was significantly reduced by antiviral therapy, from 12.9 (range 6.2-17.9) kPa to 6.6 (4.4-10.3) kPa measured at an interval of 512 (range 366-728) days (P<0.0001). Eleven of 19 (58%) patients with baseline fibrosis stages of F3-4 deduced from LS had 2-point or greater reductions of deduced stage at the last LS measurement. The change ratio of hyaluronic acid (P=0.0390) was associated with a 2-point or greater reduction of deduced fibrosis stage. Without antiviral therapy, LS tended to increase, increasing from 6.1 (range 3.9-8.5) kPa to 6.3 (range 4.4-9.7) kPa at an interval of 422 (range 358-709) days (P=0.0682). Conclusions: LS was significantly correlated with fibrosis stage in patients with chronic hepatitis B. The reduction of LS by antiviral therapy was significantly correlated with the reduction of hyaluronic acid. Thus, we conclude that LS can be useful to assess the progression and regression of liver fibrosis stage noninvasively. Springer, 2011 Hepatitis B nationallicence Antiviral therapy nationallicence Liver stiffness nationallicence Transient elastography nationallicence Fibrosis stage nationallicence LS : Liver stiffness nationallicence HBV : Hepatitis B virus nationallicence HCC : Hepatocellular carcinoma nationallicence TE : Transient elastography nationallicence kPa : Kilopascals nationallicence ROC : Receiver operating characteristics nationallicence AST : Aspartate aminotransferase nationallicence ALT : Alanine aminotransferase nationallicence APRI : Aminotransferase-to-platelet ratio index nationallicence Osakabe Keisuke Faculty of Medical Technology, School of Health Sciences, Fujita Health University, Aichi, Japan aut Ichino Naohiro Faculty of Medical Technology, School of Health Sciences, Fujita Health University, Aichi, Japan aut Nishikawa Toru Department of Clinical Laboratory, Fujita Health University Hospital, Aichi, Japan aut Sugiyama Hiroko Department of Clinical Laboratory, Fujita Health University Hospital, Aichi, Japan aut Kato Miho Department of Clinical Laboratory, Fujita Health University Hospital, Aichi, Japan aut Kitahara Shiho Department of Clinical Laboratory, Fujita Health University Hospital, Aichi, Japan aut Hashimoto Senju Department of Liver, Biliary Tract and Pancreas Diseases, Fujita Health University, 1-98 Dengakugakubo, Kutsukake, 470-1192, Toyoake, Aichi, Japan aut Kawabe Naoto Department of Liver, Biliary Tract and Pancreas Diseases, Fujita Health University, 1-98 Dengakugakubo, Kutsukake, 470-1192, Toyoake, Aichi, Japan aut Harata Masao Department of Liver, Biliary Tract and Pancreas Diseases, Fujita Health University, 1-98 Dengakugakubo, Kutsukake, 470-1192, Toyoake, Aichi, Japan aut Nitta Yoshifumi Department of Liver, Biliary Tract and Pancreas Diseases, Fujita Health University, 1-98 Dengakugakubo, Kutsukake, 470-1192, Toyoake, Aichi, Japan aut Murao Michihito Department of Liver, Biliary Tract and Pancreas Diseases, Fujita Health University, 1-98 Dengakugakubo, Kutsukake, 470-1192, Toyoake, Aichi, Japan aut Nakano Takuji Department of Liver, Biliary Tract and Pancreas Diseases, Fujita Health University, 1-98 Dengakugakubo, Kutsukake, 470-1192, Toyoake, Aichi, Japan aut Shimazaki Hiroaki Department of Liver, Biliary Tract and Pancreas Diseases, Fujita Health University, 1-98 Dengakugakubo, Kutsukake, 470-1192, Toyoake, Aichi, Japan aut Arima Yuko Department of Liver, Biliary Tract and Pancreas Diseases, Fujita Health University, 1-98 Dengakugakubo, Kutsukake, 470-1192, Toyoake, Aichi, Japan aut Suzuki Koji Faculty of Medical Technology, School of Health Sciences, Fujita Health University, Aichi, Japan aut Yoshioka Kentaro Department of Liver, Biliary Tract and Pancreas Diseases, Fujita Health University, 1-98 Dengakugakubo, Kutsukake, 470-1192, Toyoake, Aichi, Japan aut Journal of Gastroenterology Springer Japan 46/11(2011-11-01), 1324-1334 0944-1174 46:11<1324 2011 46 535 https://doi.org/10.1007/s00535-011-0444-4 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s00535-011-0444-4 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Osakabe Keisuke Faculty of Medical Technology, School of Health Sciences, Fujita Health University, Aichi, Japan aut NATIONALLICENCE 700 1- Ichino Naohiro Faculty of Medical Technology, School of Health Sciences, Fujita Health University, Aichi, Japan aut NATIONALLICENCE 700 1- Nishikawa Toru Department of Clinical Laboratory, Fujita Health University Hospital, Aichi, Japan aut NATIONALLICENCE 700 1- Sugiyama Hiroko Department of Clinical Laboratory, Fujita Health University Hospital, Aichi, Japan aut NATIONALLICENCE 700 1- Kato Miho Department of Clinical Laboratory, Fujita Health University Hospital, Aichi, Japan aut NATIONALLICENCE 700 1- Kitahara Shiho Department of Clinical Laboratory, Fujita Health University Hospital, Aichi, Japan aut NATIONALLICENCE 700 1- Hashimoto Senju Department of Liver, Biliary Tract and Pancreas Diseases, Fujita Health University, 1-98 Dengakugakubo, Kutsukake, 470-1192, Toyoake, Aichi, Japan aut NATIONALLICENCE 700 1- Kawabe Naoto Department of Liver, Biliary Tract and Pancreas Diseases, Fujita Health University, 1-98 Dengakugakubo, Kutsukake, 470-1192, Toyoake, Aichi, Japan aut NATIONALLICENCE 700 1- Harata Masao Department of Liver, Biliary Tract and Pancreas Diseases, Fujita Health University, 1-98 Dengakugakubo, Kutsukake, 470-1192, Toyoake, Aichi, Japan aut NATIONALLICENCE 700 1- Nitta Yoshifumi Department of Liver, Biliary Tract and Pancreas Diseases, Fujita Health University, 1-98 Dengakugakubo, Kutsukake, 470-1192, Toyoake, Aichi, Japan aut NATIONALLICENCE 700 1- Murao Michihito Department of Liver, Biliary Tract and Pancreas Diseases, Fujita Health University, 1-98 Dengakugakubo, Kutsukake, 470-1192, Toyoake, Aichi, Japan aut NATIONALLICENCE 700 1- Nakano Takuji Department of Liver, Biliary Tract and Pancreas Diseases, Fujita Health University, 1-98 Dengakugakubo, Kutsukake, 470-1192, Toyoake, Aichi, Japan aut NATIONALLICENCE 700 1- Shimazaki Hiroaki Department of Liver, Biliary Tract and Pancreas Diseases, Fujita Health University, 1-98 Dengakugakubo, Kutsukake, 470-1192, Toyoake, Aichi, Japan aut NATIONALLICENCE 700 1- Arima Yuko Department of Liver, Biliary Tract and Pancreas Diseases, Fujita Health University, 1-98 Dengakugakubo, Kutsukake, 470-1192, Toyoake, Aichi, Japan aut NATIONALLICENCE 700 1- Suzuki Koji Faculty of Medical Technology, School of Health Sciences, Fujita Health University, Aichi, Japan aut NATIONALLICENCE 700 1- Yoshioka Kentaro Department of Liver, Biliary Tract and Pancreas Diseases, Fujita Health University, 1-98 Dengakugakubo, Kutsukake, 470-1192, Toyoake, Aichi, Japan aut NATIONALLICENCE 773 0- Journal of Gastroenterology Springer Japan 46/11(2011-11-01), 1324-1334 0944-1174 46:11<1324 2011 46 535 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer